Comparison of DVH-based plan verification methods for VMAT: ArcCHECK-3DVH system and dynalog-based dose reconstruction

Masahide Saito | Noriyuki Kadoya | Kiyokazu Sato | Kengo Ito | Suguru Dobashi | Ken Takeda | Hiroshi Onishi | Keiichi Jingu

Abstract

The purpose of this study was comparing dose-volume histogram (DVH)-based plan verification methods for volumetric modulated arc therapy (VMAT) pretreatment QA. We evaluated two 3D dose reconstruction systems: ArcCHECK-3DVH system (Sun Nuclear corp.) and Varian dynalog-based dose reconstruction (DBDR) system, developed in-house. Fifteen prostate cancer patients (67.6 Gy/26 Fr), four head and neck cancer patient (66 Gy/33 Fr), and four esophagus cancer patients (60 Gy/30 Fr) treated with VMAT were studied. First, ArcCHECK measurement was performed on all plans; simultaneously, the Varian dynalog data sets that contained the actual delivered parameters (leaf positions, gantry angles, and cumulative MUs) were acquired from the Linac control system. Thereafter, the delivered 3D patient dose was reconstructed by 3DVH software (two different calculating modes were used: High Sensitivity (3DVH-HS) and Normal Sensitivity (3DVH-NS)) and in-house DBDR system. We evaluated the differences between the TPS-calculated dose and the reconstructed dose using 3D gamma passing rates and DVH dose index analysis. The average 3D gamma passing rates (3%/3 mm) between the TPS-calculated dose and the reconstructed dose were 99.1 ± 0.6%, 99.7 ± 0.3%, and 100.0 ± 0.1% for 3DVH–HS, 3DVH–NS, and DBDR, respectively. For the prostate cases, the average differences between the TPS-calculated dose and reconstructed dose in the PTV mean dose were 1.52 ± 0.50%, –0.14 ± 0.55%, and –0.03 ± 0.07% for 3DVH–HS, 3DVH–NS, and DBDR, respectively. For the head and neck and esophagus cases, the dose difference to the TPS-calculated dose caused by an effect of heterogeneity was more apparent under the 3DVH dose reconstruction than the DBDR. Although with some residual dose reconstruction errors, these dose reconstruction methods can be clinically used as effective tools for DVH-based QA for VMAT delivery.

PACS
87.53.Tf

KEY WORDS
dose reconstruction, patient QA, radiotherapy, VMAT
1 INTRODUCTION

Recently, volumetric modulated arc radiotherapy (VMAT) has become a routine technique in many facilities. Although this technique improves the conformity of dose distribution to PTV and reduces the impact on OARs, its use in a complex dose distribution with a sharp gradient necessitates patient-specific quality assurance (QA). The most frequently employed method for QA has been comparison of the calculated and measured doses in a phantom. Particularly, the point dose on an ion chamber and planar dose distribution on a film are usually measured. In general, gamma analysis has been used to compare measured and calculated dose distributions in a commercial radiation treatment planning system (TPS). However, these conventional patient-specific QA procedures are very time consuming for the clinical staff. In addition, some previous studies showed that gamma analysis cannot directly predict the actual patient dose.

To tackle these problems, some independent dose reconstruction methods have been proposed to evaluate patient dose—volume histogram (DVH) and dose index for VMAT pretreatment QA. One of the methods is called measurement-guided dose reconstruction (MGDR), a system which is commercially provided as MatriXX-COMPASS (IBA Dosimetry, Schwarzenbruck, Germany), Delta4 anatomy (ScandiDos, Inc., Ashland, VA, USA), and ArcCHECK-3DVH (Sun Nuclear Corporation, Melbourne, FL, USA). The ArcCHECK-3DVH system delivers a 3D patient dose that can be reconstructed using 3DVH software from the original TPS plan and ArcCHECK measurement data. The reconstructed dose from this system could be compared with the TPS-calculated dose using 3D gamma and DVH dose index analyses. The accuracy of the system has already been investigated in several studies.

Another method is machine log file-based dose reconstruction. Some have reported the use of log files generated by multi-leaf collimator (MLC) controller as a tool for DVH-based dose verification for patient-specific QA of intensity-modulated radiotherapy (IMRT). In VMAT, on the other hand, machine log files that contain other dynamic parameters (gantry angles and cumulative MU) are generated from a Linac control system. Some studies demonstrated dose reconstruction methods that modify TPS plan data using delivered parameters from these log files and recalculate by TPS dose calculation algorithm. Furthermore, Teke et al. showed that VMAT QA based on machine log files could be performed with Monte Carlo simulation.

Therefore, many approaches to DVH-based QA have been proposed and verified for accuracy. However, there have been few studies that directly compared these different DVH-based QA systems. Tyagi et al. evaluated the accuracy of dose reconstruction by the ArcCHECK-3DVH system and the machine log file-based system on only 1–2 patients for each treatment site. Therefore, to integrate this DVH-based patient-specific QA into clinical practice, we further investigated its accuracy for dose reconstruction. The purpose of this study was to compare two DVH-based plan verification methods for VMAT pretreatment QA. These two 3D dose reconstruction systems were the ArcCHECK-3DVH and the Varian dynalog-based dose reconstruction (DBDR).

2 METHODS

2A VMAT plans

Fifteen prostate cancer patients (67.6 Gy/26 Fr), four head and neck cancer patients (66 Gy/33 Fr), and four esophageal cancer patients (60 Gy/30 Fr) treated with VMAT were studied. Single- (179°–181°, counter-clockwise) or double- (179°–179°, counter-clockwise and clockwise) or triple- (179°–181°, counter-clockwise, clockwise, and counter-clockwise) full arc plans were generated by experienced medical physicists using Eclipse TPS ver.8.6 (Varian Medical Systems, Palo Alto, CA, USA). The anisotropic analytical algorithm (AAA) ver.11.0.1 with a 2-mm grid was used for dose calculation. All VMAT plans were delivered by 6 MV or 15 MV X-ray beams of Varian 23EX with a 120 millennium MLC.

2B ArcCHECK-3DVH system

The ArcCHECK-3DVH system (Sun Nuclear Corporation, Melbourne, FL, USA) was commercially available tool for DVH-based QA. ArcCHECK was cylindrical 3D diode array, which contained 1386 diodes (detector size: 0.8 × 0.8 mm²) in a helical arrangement at intervals of 10 mm and with diameter of 21 cm. To reconstruct an “actual” 3D patient dose from the measured ArcCHECK data, we used 3DVH software ver. 3.2 that had an internal calculation engine, which was called ArcCHECK planned dose perturbation (ACPDP). To perform ACPDP, the following data set were prepared: reference DICOM RT plan, DICOM RT dose (TPS-calculated dose for the patient and ArcCHECK geometries, respectively), and ArcCHECK measurement data (acml). The ACPDP algorithm involved the following calculation steps: (a) synchronizing the planned data with the ArcCHECK virtual inclinometer recorded data; (b) generating a relative 3D dose grid to a homogeneous cylindrical phantom for each sub-beam; (c) morphing the relative dose based on the ArcCHECK-measured data to produce the 3D absolute dose in the cylindrical phantom; (d) taking the ratio of the reconstructed dose to the TPS-calculated dose for each voxel in the phantom; and (e) perturbing the TPS-calculated dose of the patient by the above ratios. The final grid size of the reconstructed dose was the same as that of the TPS dose calculation. Further details on ACPDP have been described elsewhere. In addition to ACPDP calculation step 3, two different modes were used in this study; these were High Sensitivity (3DVH–HS) and Normal Sensitivity (3DVH–NS) modes. There were two conditions in which 3DVH–NS dose morphing was dampened per diode: (a) if the dose of the diode was below a qualifying threshold dose and (b) the diode was in a very high gradient region. On the other hand, a high range 3DVH–HS dose morphing was possible even in steep dose gradients for the 4D sub-beams and in high- and low-dose regions.
The 3DVH–HS dose morphing is recommended for detecting even very small deviations from ideal behavior.

2.C  In-house dynalog-based dose reconstruction system

In VMAT, two sets of Varian dynalog were generated. One was beam delivery dynalog, which was created by the Linac console and contained information delivered from the dynamic beam (e.g., the actual cumulative dose delivered (MU) versus the actual gantry angle); these parameters were only recorded for each control point. The other log was the MLC dynalog, which was created by the MLC controller. The file was separately generated and acquired every 50 ms for the MLC banks A and B. Details of the MLC dynalog have been described elsewhere.23 In this study, dynalog-based dose reconstruction (DBDR) was performed by an in-house software and Eclipse TPS. First, the original DICOM RT plan from Eclipse TPS was modified by the in-house software using the two dynalog sets. Particularly, control point information of the originally planned parameters (leaf positions, gantry angles, and cumulative MU weights) was rewritten to the actual delivered parameters recorded in the dynalog sets. The in-house software was developed by Visual C++ and open source DICOM tool kit DCMTK ver. 3.6.0. The DICOM RT plan reconstructed by the software was placed back to Eclipse TPS, and the actual patient 3D dose was recalculated by the TPS dose calculation algorithm (AAA).

2.D  Validation of the in-house DBDR system

Before using the in-house DBDR system for patient-specific QA, the system was validated by a method similar to the one used by Juan et al. to check for programming errors.7 For a baseline plan (Single-arc prostate VMAT, 2.6 Gy/1 Fr), nine MLC error plans were generated (Table 1). To measure the absolute dose at the center of the phantom, these plans were delivered by a 15-MV X-ray beam of Varian 23EX with a 120 millennium MLC to an ArcCHECK phantom. The values for the error/baseline ratio showed a significant positive correlation (R2 = 0.986; P < 0.01) between the measurement values and accuracy limit values for each DVH dose index using the following eq. (1)

\[ \text{Confidence limit} = |\text{DD}_{\text{mean}}| + 1.96 \times \text{DD}_{\text{SD}} \]

where DD_{\text{mean}} was the average dose differences between the TPS-calculated dose and the reconstructed dose and DD_{\text{SD}} was the standard deviation. All 3D analyses were performed in 3DVH software ver.3.2.

3  RESULTS

3.A  Validation of the in-house DBDR System

The results of validation of the in-house DBDR system are summarized in Table 1. Nine MLC error plans (#1–9) were created for baseline plan (#0), and irradiated to 0.6-cc Farmer ion chamber in center of ArcCHECK phantom. The values for the error/baseline ratio showed a significant positive correlation (R2 = 0.986; P < 0.01) between the measurement values and DBDR values. Although we validated the system using MLC error plans without accounting for gantry angle and MU errors, we confirmed that the system could work correctly in dynamic irradiation.

3.B  Analysis of DVH-based QA

Before 3D reconstructed dose analysis, we evaluated the 2D planar dose that was measured by ArcCHECK for all patients using SNC.

### Table 1  Comparisons between ion chamber measurement and reconstructed dose by in-house DBDR system in center of ArcCHECK phantom.

| Plan name          | D_{\text{Mean}} | Error/Baseline | D_{\text{DBDR}} | Error/Baseline |
|--------------------|-----------------|----------------|-----------------|----------------|
| 0  Baseline        | 2.56            | –              | 2.55            | –              |
| 1  1 mm MLC Gap opening | 2.70  | 1.05           | 2.67            | 1.05           |
| 2  1 mm MLC Opening bank A  | 2.63  | 1.03           | 2.59            | 1.02           |
| 3  1 mm MLC Opening bank B  | 2.65  | 1.03           | 2.62            | 1.03           |
| 4  1 mm MLC Gap closing       | 2.45  | 0.96           | 2.44            | 0.96           |
| 5  1 mm MLC Closing bank A    | 2.52  | 0.98           | 2.51            | 0.98           |
| 6  1 mm MLC Closing bank B    | 2.50  | 0.98           | 2.48            | 0.97           |
| 7  1 mm MLC Shift bank A      | 2.55  | 1.00           | 2.52            | 0.99           |
| 8  1 mm MLC Shift bank B      | 2.58  | 1.01           | 2.57            | 1.01           |
| 9  Random error         | 2.57  | 1.00           | 2.55            | 1.00           |

D_{\text{mean}}: absolute dose measured by ion chamber; D_{\text{DBDR}}: absolute dose calculated by in-house Dynalog-based dose reconstruction method.
Fig. 1. A schematic design of this study. Two 3D patient-specific QA methods (using ArcCHECK-3DVH system and in-house DBDR system) were carried out simultaneously, and the reconstructed doses were compared to TPS-calculated dose.

Fig. 2. A representative 3D dose validation result (patient 4). Reference TPS-calculated dose (upper left), DVHs of PTV, rectum wall and bladder wall for each reconstructed dose (bottom left), and each reconstructed dose distribution and the difference maps to TPS-calculated dose of each method (right).
Patient software ver. 6.6 (Sun Nuclear Corporation, Melbourne, FL, USA). 2D gamma analysis showed good agreement between the measured and calculated planar doses (gamma passing rate > 97.5% for all patients (3%/3 mm, global normalization, threshold 10%)), indicating that conventional 2D patient-specific QA was mostly successful.

Table 2 shows a representative DVH-based QA for patient 4; the reconstructed dose distribution of each method, the difference map to reference TPS-calculated dose, and DVHs of this patient are shown. For 3DVH methods, there were differences observed between the TPS-calculated and reconstructed doses. In addition, a difference between 3DVH-HS and 3DVH-NS was observed. On the other hand, using the in-house DBDR method, there were little differences between the TPS-calculated and reconstructed doses.

Table 2 shows the whole-body 3D gamma passing rates for all patient. The average whole-body 3D gamma passing rates (3%/3 mm) were 99.1 ± 0.6%, 99.7 ± 0.3%, and 100.0 ± 0.1% for 3DVH-HS, 3DVH-NS, and DBDR, respectively. The results of DVH-based QA for each DVH dose index and the confidence limits are summarized in Table 3. These dose differences varied for each reconstruction method and DVH dose index. The confidence limits in this study were within 9.67% for 3DVH-HS, 9.72% for 3DVH-NS, and 3.64% for DBDR.

Table 2 3D global gamma passing rates (Threshold = 10%) between TPS-calculated dose and each dose reconstruction method for all patients.

| Patient No. | Treatment site |  1%/2 mm |  2%/2 mm |  3%/3 mm |
|-------------|----------------|----------|----------|----------|
|             | 3DVH-HS | 3DVH-NS | DBDR  | 3DVH-HS | 3DVH-NS | DBDR  | 3DVH-HS | 3DVH-NS | DBDR  |
| 1 Prostate  | 96      | 94.4    | 99.8    | 99      | 98.9    | 100    | 99.8    | 99.8    | 100    |
| 2 Prostate  | 94      | 93.8    | 100     | 98.2    | 98.6    | 100    | 99.5    | 99.7    | 100    |
| 3 Prostate  | 94.2    | 94.5    | 100     | 98.4    | 99.1    | 100    | 96.6    | 99.9    | 100    |
| 4 Prostate  | 89.3    | 91      | 100     | 95.5    | 98.1    | 100    | 98.6    | 99.7    | 100    |
| 5 Prostate  | 95.2    | 95.3    | 100     | 98.2    | 99.4    | 100    | 99.4    | 99.9    | 100    |
| 6 Prostate  | 96.2    | 96.1    | 100     | 98.8    | 99.4    | 100    | 99.6    | 99.8    | 100    |
| 7 Prostate  | 96.4    | 96.5    | 100     | 98.9    | 98.9    | 100    | 99.6    | 99.8    | 100    |
| 8 Prostate  | 96.3    | 96.1    | 100     | 98.6    | 99.3    | 100    | 99.5    | 99.8    | 100    |
| 9 Prostate  | 94.3    | 94.1    | 100     | 98.2    | 99      | 100    | 99.4    | 99.8    | 100    |
| 10 Prostate | 93      | 94.2    | 100     | 97.4    | 99.2    | 100    | 99.1    | 99.8    | 100    |
| 11 Prostate | 90.3    | 91.1    | 100     | 95.1    | 97.2    | 100    | 98      | 99.3    | 100    |
| 12 Prostate | 93.7    | 93.9    | 100     | 97.9    | 99      | 100    | 99.3    | 99.7    | 100    |
| 13 Prostate | 96.1    | 96.4    | 100     | 98.5    | 99.2    | 100    | 99.4    | 99.8    | 100    |
| 14 Prostate | 90.1    | 90.2    | 100     | 96      | 97.9    | 100    | 98.4    | 99.5    | 100    |
| 15 Prostate | 87.9    | 87.3    | 100     | 93.7    | 95.7    | 100    | 97.2    | 98.7    | 100    |
| 16 Head and neck | 89.6 | 92.8 | 98.3 | 95 | 98 | 99.8 | 98.8 | 99.7 | 100 |
| 17 Head and neck | 87.9 | 91.9 | 98.8 | 96.3 | 98.5 | 99.9 | 95.5 | 99.9 | 100 |
| 18 Head and neck | 82     | 86.8    | 95.9    | 92.4    | 96.2    | 98.7    | 99.1    | 99.7    | 99.9 |
| 19 Head and neck | 86.8 | 93      | 98      | 94      | 98.3    | 99.7    | 99      | 99.9    | 100    |
| 20 Esophagus | 89.7    | 86.8    | 98.5    | 97.7    | 97.4    | 99.8    | 99.4    | 99.2    | 100    |
| 21 Esophagus | 88.2    | 90.9    | 92      | 96.1    | 98.9    | 97.8    | 99.4    | 99.9    | 99.5    |
| 22 Esophagus | 73      | 75.5    | 94.4    | 87.1    | 94.1    | 100    | 98      | 99.6    | 100    |
| 23 Esophagus | 88.3    | 92      | 98.4    | 97.7    | 99.5    | 99.9    | 99.8    | 100    | 100   |
| Average     | 90.8    | 91.9    | 99.1    | 96.5    | 98.3    | 99.8    | 99.1    | 99.7    | 100.0 |
| S.D.        | 5.3     | 4.5     | 1.8     | 2.7     | 1.3     | 0.5     | 0.6     | 0.3     | 0.1   |

3DVH-HSm, High Sensitivity dose morphing in 3DVH software; 3DVH-NS, Normal Sensitivity dose morphing in 3DVH software; DBDR, in-house Dynalog-based dose reconstruction method.

3DVH-HS, 3DVH-NS, and DBDR, respectively. The results of DVH-based QA for each DVH dose index and the confidence limits are summarized in Table 3. These dose differences varied for each reconstruction method and DVH dose index. The confidence limits in this study were within 9.67% for 3DVH-HS, 9.72% for 3DVH-NS, and 3.64% for DBDR.

Figure 3 shows dose differences in parameter mean dose (Dmean) and maximum dose (Dmax) for the target volume (PTV) between TPS-calculated dose and each reconstructed dose, for all prostate patients. Although there were good agreements between the TPS-calculated dose and the DBDR dose for all prostate patients, the systematic errors for the Dmax were observed in 3DVH methods compared with DBDR. Figure 4 shows the typical prostate patient (patient 8) with a trend toward higher dose in the target volume for the 3DVH reconstructed dose. The average differences between the TPS-calculated dose and reconstructed dose in the PTV mean dose of the prostate patients were 1.52 ± 0.50%.
Dmax of the prostate patients were 6.24 ± 0.14, respectively. On the other hand, the average differences of all DVH parameters calculated by the eq. (1) in the text. Thereafter, we compared these methods using 3D analysis, showing that the system was a well-developed DVH-based QA tool.

In this study, before comparing two DVH-based QA methods that were the ArcCHECK-3DVH system and the in-house DBDR system, we validated the in-house DBDR system using MLC error plans, showing that the system was a well-developed DVH-based QA tool. Thereafter, we compared these methods using 3D analysis, showing that the ArcCHECK-3DVH system had some differences from the in-house DBDR system.

The accuracy of the ArcCHECK-3DVH system has been validated by several authors, such as Olch et al., who used ion chamber and EDR2 film, and Watanabe et al., who used BANG3 polymer gel dosimeter. Furthermore, using error-induced plans, Kadoya et al. reported that 3DVH–NS was better than 3DVH–HS in terms of dose reconstruction accuracy. These findings were consistent with our results in the present study. Particularly, compared with 3DVH–HS, the 3DVH–NS had a dose distribution that was in good agreement with the TPS-calculated dose distribution (Fig. 2). In addition, 3DVH methods use the ACPDP model parameters optimized in other facilities beforehand. Therefore, for DVH dose index analysis, the systematics for a specific DVH parameter were observed in 3DVH software; 3DVH–NS, Normal Sensitivity dose morphing in 3DVH software; DBDR, in-house Datalog-based dose reconstruction method.

### Table 3

| Treatment site | Structure | Dose index | Difference to TPS calculated value (%) | Confidence limits (%) |
|---------------|-----------|------------|---------------------------------------|-----------------------|
| (n=15)        | PTV       | Dmean      | 1.52 ± 0.50 | −0.14 ± 0.55, −0.03 ± 0.07 | 2.49 ± 0.12 ± 0.17 |
|               |           | DSS        | 0.91 ± 0.55 | −0.82 ± 0.60, −0.07 ± 0.11 | 1.99 ± 0.19 ± 0.29 |
|               |           | Dmax       | 6.24 ± 1.70 | 4.73 ± 1.66, −0.15 ± 0.36  | 9.57 ± 7.98 ± 0.86 |
|               | Rectum    | Dmean      | 1.74 ± 0.59 | 0.04 ± 0.48, −0.25 ± 0.14  | 2.91 ± 0.98 ± 0.52 |
|               |           | VSS        | 0.31 ± 1.45 | −1.91 ± 1.13, −0.39 ± 0.31 | 3.16 ± 4.12 ± 0.99 |
|               |           | VSS        | 4.21 ± 1.54 | 1.63 ± 1.39, −0.51 ± 0.36  | 7.23 ± 4.35 ± 1.21 |
|               | Bladder   | Dmean      | 1.71 ± 0.67 | 1.34 ± 1.23, −0.15 ± 0.14  | 3.02 ± 3.75 ± 0.43 |
|               |           | VSS        | 0.44 ± 0.58 | −0.55 ± 0.59, −0.15 ± 0.15 | 1.58 ± 1.71 ± 0.44 |
|               |           | VSS        | 2.34 ± 0.90 | 0.72 ± 0.95, −0.38 ± 0.22  | 4.09 ± 2.59 ± 0.82 |
| (n=4)         | PTV       | DSS        | 1.43 ± 0.25 | 0.37 ± 0.42, 0.15 ± 0.04   | 1.92 ± 1.19 ± 0.23 |
|               | Brain stem| Dmax       | 3.76 ± 0.92 | 2.98 ± 0.78, 0.76 ± 0.61   | 5.57 ± 4.51 ± 1.95 |
|               | Spinal cord| Dmax      | 3.01 ± 1.07 | 1.81 ± 0.48, 0.17 ± 0.32   | 5.12 ± 2.75 ± 0.80 |
|               | Right parotid| Dmax       | 2.76 ± 0.90 | 1.76 ± 0.78, 0.37 ± 0.36   | 4.52 ± 3.29 ± 1.07 |
|               | Left parotid| Dmax       | 0.83 ± 0.7  | −0.57 ± 0.82, 1.49 ± 1.08  | 2.21 ± 1.03 ± 3.62 |
| (n=4)         | PTV       | DSS        | 1.87 ± 0.61 | 1.25 ± 0.81, 0.06 ± 0.11   | 3.07 ± 2.83 ± 0.27 |
|               | Lung      | Dmean      | 1.57 ± 0.39 | 1.81 ± 0.65, −0.03 ± 0.11  | 2.33 ± 3.10 ± 0.18 |
|               | Spinal cord| Dmax       | 2.18 ± 1.93 | 0.79 ± 2.53, 1.09 ± 1.30   | 5.97 ± 5.76 ± 3.64 |

3DVH–HS, High Sensitivity dose morphing in 3DVH software; 3DVH–NS, Normal Sensitivity dose morphing in 3DVH software; DBDR, in-house Datalog-based dose reconstruction method.

−0.14 ± 0.55%, and −0.03 ± 0.07% for 3DVH–HS, 3DVH–NS, and DBDR, respectively. On the other hand, the average differences between the TPS-calculated dose and reconstructed dose in the PTV Dmax of the prostate patients were 6.24 ± 1.70%, 4.73 ± 1.66%, and −0.15 ± 0.36% for 3DVH–HS, 3DVH–NS, and DBDR, respectively.

In addition, each reconstructed dose was affected by heterogeneities as shown in Figs. 5 and 6. Especially, increasing low dose region in the organ that includes air cavity such as paranasal sinus, trachea, and lungs was observed. The results of DVH-based QA for each DVH dose index and the confidence limits for the heterogeneous sites are also summarized in Table 2.

### 4 DISCUSSION

In this study, before comparing two DVH-based QA methods that were the ArcCHECK-3DVH system and the in-house DBDR system, we validated the in-house DBDR system using MLC error plans, showing that the system was a well-developed DVH-based QA tool. Thereafter, we compared these methods using 3D analysis, showing that the ArcCHECK-3DVH system had some differences from the in-house DBDR system.

The accuracy of the ArcCHECK-3DVH system has been validated by several authors, such as Olch et al., who used ion chamber and EDR2 film, and Watanabe et al., who used BANG3 polymer gel dosimeter. Furthermore, using error-induced plans, Kadoya et al. reported that 3DVH–NS was better than 3DVH–HS in terms of dose reconstruction accuracy. These findings were consistent with our results in the present study. Particularly, compared with 3DVH–HS, the 3DVH–NS had a dose distribution that was in good agreement with the TPS-calculated dose distribution (Fig. 2). In addition, 3DVH methods use the ACPDP model parameters optimized in other facilities beforehand. Therefore, for DVH dose index analysis, the systematic errors for a specific DVH parameter were observed in 3DVH methods than DBDR (Fig. 3). In addition, we evaluated the method under the heterogeneous treatment sites (Figs. 5 and 6). The 3DVH reconstructed dose is calculated by dose ratio map between ACPDP and TPS based on the homogeneity cylindrical phantom. Therefore, the effect of heterogeneity is not considered under the dose reconstruction, resulting in a change of the dose distribution especially in the heterogeneous region such as paranasal sinus and lungs.
The dose difference of the in-house DBDR system from the TPS-calculated dose was smaller than that of the ArcCHECK-3DVH system. This result was congruent with the results of previous studies. The improvement in dose reconstruction accuracy may have been due to identical dose calculation algorithm for both treatment planning and DBDR. That is, the errors caused by the different
dose calculation algorithms were zero in log file-based dose reconstruction method. Therefore, in contrast to the 3DVH method, the dose distribution using DBDR method was good agreement to the TPS-calculated dose even under the heterogeneous situation. Although machine log file-based dose reconstruction may be useful for patient-specific QA, only few hospitals use this method. Further evidence is needed to implement this method into clinical practice. In this study, the measured dose with the ArcCHECK and the machine log file were acquired only once for each plan, respectively. This is a limitation of the study and the reproducibility of each reconstruction method remained to be evaluated in further study. However, in clinical practice, multiple measurements are not allowed depending on the situation such as in vivo QA using the DBDR method with cone-beam computed tomography. Furthermore, it is

**Fig. 5.** Dose distribution of each reconstruction method for the typical head and neck cancer case (patient 18). Reference TPS-calculated dose (a), reconstructed dose using DBDR (b), 3DVH-HS (c), and 3DVH-NS (d) are represented. The DBDR dose was similar to the reference TPS-calculated dose. On the other hand, increasing the low dose region in the paranasal sinus that indicated by the white arrows was observed for the 3DVH reconstructed dose.

**Fig. 6.** Dose distribution of each reconstruction method for the typical esophagus cancer case (patient 21). Reference TPS-calculated dose (a), reconstructed dose using DBDR (b), 3DVH-HS (c), and 3DVH-NS (d) are represented. The DBDR dose was similar to the reference TPS-calculated dose. On the other hand, increasing the low dose region in the right lung that indicated by the white arrows was observed for the 3DVH reconstructed dose.
important to simplify the procedures to reduce the burden on clinical staff. Therefore, our results will serve to help medical physicists to understand the reliability of once measurement of each dose reconstructed method.

Some previous studies on large planning data (700 cases of Head and Neck VMAT, and 73 cases of prostate VMAT) were reported for the MatriXX-COMPASS system, one of the DVH-based QA methods of using MGDR.\textsuperscript{14,15} On the other hand, there have been no large-scale studies on ArcCHECK-3DVH system and machine log-file based dose reconstruction. In this study, we investigated the accuracy of different dose reconstruction methods on 15 prostate, 4 head and neck, and 4 esophagus VMAT patients. We calculated the confidence limit for each DVH-based QA metrics (Table 3). In terms of tolerance for DVH-based patient-specific QA, Visser et al. suggested that action levels may clearly distinguish the role of the medical physicist and radiation oncologist during the QA procedure.\textsuperscript{14} Our results indicate that these confidence limits may be used by medical physicists.

5 | CONCLUSION

The two DVH-based QA methods that we evaluated in this study had different dose reconstruction accuracies. Although with some residual dose reconstruction errors, these two methods can be clinically used as effective tools for DVH-based QA for VMAT.

CONFLICT OF INTEREST

There is no conflict of interest with regard to this manuscript.

REFERENCES

1. Low DA, Harms WB, Mutic S, Purdy JA. A technique for the quantitative evaluation of dose distributions. Med Phys. 1998;25: 656–661.
2. Nelms BE, Zhen H, Tomé WA. Per-beam, planar IMRT QA passing rates do not predict clinically relevant patient dose errors. Med Phys. 2011;38:1037.
3. Carrasco P, Jornet N, Latorre A, Eudaldo T, Ruiz A, Ribas M. 3D DVH-based metric analysis versus per-beam planar analysis in IMRT pretreatment verification. Med Phys. 2012;39:5040–5049.
4. Olch AJ. Evaluation of the accuracy of 3DVH software estimates of dose to virtual ion chamber and film in composite IMRT QA. Med Phys. 2012;39:81–86.
5. Watanabe Y, Nakaguchi Y. 3D evaluation of 3DVH program using BANG3 polymer gel dosimeter. Med Phys. 2013;40:82101.
6. Kadoya N, Saito M, Ogawara M, et al. Evaluation of patient DVH-based QA metrics for prostate VMAT: correlation between accuracy of estimated 3D patient dose and magnitude of MLC misalignment. J Appl Clin Med Phys. 2015;16:5251.
7. Calvo-Ortega JF, Teke T, Moragues S, Pozo M, Casals J A Varian dynalog file-based procedure for patient dose-volume histogram-based IMRT QA. J Appl Clin Med Phys. 2014;15:100.
8. Haga A, Sakumi A, Okano Y, et al. Dose verification of volumetric modulated arc therapy (VMAT) by use of in-treatment linac parameters. Radiol Phys Technol. 2013;6:335–342.
9. Peng J, Zhang Z, Zhou L, et al. A study on investigating the delivery parameter error effect on the variation of patient quality assurance during RapidArc treatment. Med Phys. 2013;40:3031703.
10. Teke T, Bergman AM, Kwa W, Gill B, Duzenli C, Popescu IA. Monte Carlo based, patient-specific RapidArc QA using Linac log files. Med Phys. 2010;37:116.
11. Tyagi N, Yang K, Yan D. Comparing measurement-derived (3DVH) and machine logfile-derived dose reconstruction methods for VMAT QA in patient geometries. J Appl Clin Med Phys. 2014;15:54.
12. Nelms BE, Opp D, Robinson J, et al. VMAT QA: measurement-guided 4D dose reconstruction on a patient. Med Phys. 2012;39:4228–4238.
13. Kumar DM, Thirumavalavan N, Krishna VD, Babaiah M. QA of intensity-modulated beams using dynamic MLC log files. J Med Phys. 2006;31:36–41.
14. Visser R, Wauben DJ, De Groot M, et al. Evaluation of DVH-based treatment plan verification in addition to gamma passing rates for head and neck IMRT. Radiother Oncol. 2014;112:389–395.
15. Sdrolia A, Brownsword KM, Marsden JE, Alty KT, Moore CS, Beavis AW. Retrospective review of locally set tolerances for VMAT prostate patient specific QA using the COMPASS system. Phys Med. 2015;31:792–797.